R-CHOP方案治疗17例弥漫大B细胞型淋巴瘤临床观察

An Observation of the Therapeutic Effects with R-CHOP Regimen in Diffuse Large B-cell Lymphoma

目的研究利妥昔单抗联合CHOP方案治疗弥漫大B细胞型淋巴瘤的疗效和不良反应。方法17例弥漫大B细胞型淋巴瘤(DLBCL)共接受6个周期R-CHOP方案的治疗:利妥昔单抗375mg/m2第1天,环磷酰胺750mg/m2第2天,阿霉素50mg/m2第2天,长春新碱1.4mg/m2第2天,泼尼松100mg/d第2～6天。结果总缓解率为82.4%,其中完全缓解9例,完全缓解率为52.9%,5例达到部分缓解,部分缓解率29.4%。17例患者1年和2年无进展生存率分别为82.4%(14/17)和58.8%(10/17),1年和2年的总生存率分别为94.1%(16/17)和76.5%(13/17)。其不良反应主要为骨髓抑制,仅1例出现利妥昔单抗输注相关反应。结论R-CHOP方案治疗弥漫大B细胞型淋巴瘤疗效高而不良反应轻,可作为治疗该病的一线方案。

Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B-cell lymphoma（DLBCL）.Methods 17 patients diagnosed as diffuse large B-cell lymphoma and received R-CHOP regimen of 4～6 cycles.Rituximab 375mg/m^2 intravenously infusion on day 1,cyclophosphamide 750mg/m^2,adriamycin 50mg/m^2 and vincristine 1.4mg/m^2 on day 2,prednison 100mg/d orally taken on day 2～6.Results The total response rate was 82.4%,among which complete remission was seen in 9 patients（CRR： 52.9%） and partial remission was seen in 5 patients（PRR： 29.4%）.The progression freely survival rate of 1-year and 2-year were 82.4%（14/17） and 58.8%（10/17）,respectively.The overall survival rate of 1-year and 2-year were 94.1%（16/ 17） and 76.5%（13/17）.The major adverse events were myelosuppression only one dose of rituximab infusion related-toxicity was observed.Conclusions R-CHOP regimen had high of efficacywith mild toxicity in the treat-ment of DLBCL,hopefully may become a first-line therapy.